TG Therapeutics Inc (STU:NKB2)
€ 14.742 -0.034 (-0.23%) Market Cap: 2.35 Bil Enterprise Value: 2.26 Bil PE Ratio: 75.14 PB Ratio: 15.96 GF Score: 72/100

TG Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 07:00PM GMT
Release Date Price: €42.41 (-0.35%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

All right. Great. Thanks. Thanks, everyone, for joining in -- for tuning into the JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst at the firm. And our next presenting company this afternoon is TG Therapeutics. And it's my pleasure to welcome CEO, Mike Weiss, to tell us a little bit about the company. (Operator Instructions)

With that, Mike, thanks again for sharing some of your time with us out here.

Michael S. Weiss
TG Therapeutics, Inc. - CEO & President

Yes. Thanks, Eric. I really appreciate it. I want to specifically thank JPMorgan. After 8 years of presenting on a Thursday, when it doesn't matter at all, I got the Tuesday slot. So really appreciate it. So thanks all, and thanks, everyone, for joining us.

So on Slide 2, I'll be making some forward-looking statements. I do encourage folks who are interested in TG Therapeutics to review our public disclosure documents available on the Internet.

Slide 3. So just

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot